TPR is a prognostic biomarker and potential therapeutic target associated with immune infiltration in hepatocellular...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
• Understanding novel molecular markers is crucial for improving HCC patient outcomes.

Purpose of the Study:

• To investigate the role of translocated promoter region (TPR) in HCC.
• To assess the association of TPR expression with clinical outcomes, hallmarks of cancer, and the tumor immune microenvironment in HCC.

Main Methods:

• Analysis of TPR expression in HCC using multiple public databases (GEO, TCGA, GTEx, KM Plotter).
• Clinicopathological correlation and survival analysis (Cox regression, KM analysis).
• Pathway enrichment analysis (Metascape, GSEA) and immune infiltration assessment (TISIDB, TIMER).
• In vitro experiments involving TPR silencing in HCC cells.

Main Results:

• TPR expression is significantly upregulated in HCC tumor tissues compared to normal tissues.
• Higher TPR expression is associated with worse overall survival and correlates with several clinical features.
• TPR expression is linked to cell differentiation pathways and modulates the tumor immune microenvironment, including associations with immunoregulators and immune cells.
• TPR silencing inhibits AKT phosphorylation and HCC cell proliferation in vitro.

Conclusions:

• Translocated promoter region (TPR) is a potential prognostic biomarker in HCC.
• TPR may play a role in HCC progression through cell differentiation and immune modulation.
• TPR represents a promising novel therapeutic target for hepatocellular carcinoma.